
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Sabrina McCrear is an assistant editor for The American Journal of Managed Care® (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for The Center for Biosimilars, an AJMC® publication.
Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on LinkedIn.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles antibody.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Medicare Advantage exits, rising ACA premiums, a Medicare for America bill, and a Medicaid work rule ruling frame health policy on Election Day.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.

At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026 as PDP options keep shrinking.

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.

Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure.

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis C cases.

Aditi Ramakrishnan, MD, MSc, explains how pharmacy benefit gaps and prior authorization denials keep patients from long-acting injectable PrEP.

The US has curative HCV treatment and rapid tests but lags peer nations in prevention for people who inject drugs.

Published: October 13th 2026 | Updated: October 16th 2026

Published: June 1st 2026 | Updated: June 3rd 2026

November 5th 2026

November 10th 2026